VENUSREM Intraday Analysis...

VENUSREM Share Price

Open 100.60 Change Price %
High 109.40 1 Day 5.10 5.10
Low 100.60 1 Week 2.25 2.19
Close 105.15 1 Month 5.90 5.94
Volume 874516 1 Year 1.90 1.84
52 Week High 142.50
52 Week Low 65.20
VENUSREM Important Levels
Resistance 2 113.31
Resistance 1 109.95
Pivot 105.05
Support 1 100.35
Support 2 96.99
NSE INDIA Most Active Stocks
SUZLON 15.60 2.63%
ESL 5.05 8.60%
ESL 5.05 8.60%
ESL 5.05 8.60%
ESL 5.05 8.60%
NHPC 29.95 -0.83%
DLF 131.65 1.39%
PNB 130.25 1.20%
AXISBANK 487.20 2.08%
HDIL 63.50 -1.70%
More..
NSE INDIA Top Gainers Stocks
KSERASERA 0.20 33.33%
FACT 33.70 19.93%
PALREDTEC 132.00 18.17%
FCSSOFT 0.35 16.67%
JAIHINDPRO 6.95 13.93%
WEIZFOREX 213.30 12.98%
DATAMATICS 153.55 11.19%
NAHARPOLY 66.60 11.00%
MVL 0.55 10.00%
MVL 0.55 10.00%
More..
NSE INDIA Top Losers Stocks
PRADIP 1.70 -12.82%
SRGINFOTEC 0.35 -12.50%
NICCO 0.45 -10.00%
SPMLINFRA 55.30 -9.42%
ZENITHBIR 0.75 -6.25%
TECHIN 3.85 -6.10%
VISUINTL 0.80 -5.88%
INFOMEDIA 5.75 -5.74%
PENPEBS 143.55 -5.56%
PNEUMATIC 845.75 -5.50%
More..

Venus Remedies Limited (NSE: VENUSREM)

VENUSREM Technical Analysis 3
As on 17th Jan 2017 VENUSREM Share Price closed @ 105.15 and we RECOMMEND Buy for LONG-TERM with Stoploss of 94.31 & Buy for SHORT-TERM with Stoploss of 98.13 we also expect STOCK to react on Following IMPORTANT LEVELS.
VENUSREM Target for January
1st Target up-side 108.16
2nd Target up-side 116.3
3rd Target up-side 124.43
1st Target down-side 84.94
2nd Target down-side 76.8
3rd Target down-side 68.67
VENUSREM Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
VENUSREM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.venusremedies.com
VENUSREM Address
VENUSREM
Plot 51-52, Industrial Area
Phase I
Panchkula, 134113
India
Phone: 91 17 2325 0571
Fax: 91 17 2256 5566
VENUSREM Latest News
Venus Remedies bags patent for antibiotic Vancoplus   Hindu Business Line   - 09th Feb 15
Venus Remedies receives approval for pain reliever drug Trois in Singapore   Business Standard   - 30th Sep 14
Venus Remedies eyes tie-ups for out-licensing drugs   Economic Times   - 23rd Sep 14
Venus Remedies Ltd updates on downgrade by CRISIL   Equity Bulls   - 17th Sep 14
Venus Remedies looking to raise $20M through QIP   VC Circle   - 04th Sep 14
Venus Remedies - Extension of time for holding AGM   Moneycontrol.com   - 01st Sep 14
Venus Remedies Ltd rallies on strategic tie-up with Teva   Economic Times   - 27th Aug 14
Venus Remedies Ltd. : Venus Remedies signs MoU for Elores with South African ...   4-traders (press release)   - 17th Dec 13
Mr. Pawan Chaudhary, Managing Director, Venus Remedies Ltd   India Infoline.com   - 20th May 11
Pawan Chaudhary, MD, Venus Remedies Ltd.   India Infoline.com   - 17th Aug 10
Interactive Technical Analysis Chart Venus Remedies Limited ( VENUSREM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Venus Remedies Limited
VENUSREM Business Profile
Venus Remedies Limited manufactures and trades medicines in India and internationally. It primarily offers fixed dosage injectable products. The company’s product portfolio includes approximately 75 products in various therapeutic segments comprising oncology, anti infective, neurology, cardiology, orthopedic, pediatrics, and surgery. It offers its products under the Mebatic, Calridol, Moximicin, Neurotol, Glutapep, Doxol, Paxol, Citabol, Epirol, Ronem, Immunox, Pimcef, Fejet IV, Parin-E, Vanconex, Elores, Supime, Tobracef, Vancoplus, Potentox, Pirotum, and other brand names. The company was incorporated in 1989 and is headquartered in Panchkula, India.